CapEdge
Loading...
Advanced
What's new? Log in Free sign up
  • Home
  • Sectors & IndustriesSectors
  • Earnings
  • IPOs
  • SPACs
  • Transcripts
  • Insider
  • Institutional
  • Crypto
  • Screeners
  • Reddit
  • Splits
  • ENSC Dashboard
  • Financials
  • Filings
  • ETFs
  • Insider
  • Institutional
  • Shorts
  • News
  • Patents
  • Reddit

Ensysce Biosciences (ENSC)

Company Profile
Ensysce Biosciences is a clinical-stage biotech company using its proprietary technology platforms to develop safer prescription drugs. Leveraging TAAP™ and MPAR™, the Company is in the process of developing a unique, tamper-proof treatment option for pain that minimizes the risk of both drug abuse and overdoses. Ensysce’s products are anticipated to provide safer options to treat patients suffering from severe pain and assist in preventing deaths caused by medication abuse. The platforms are covered by an extensive worldwide intellectual property portfolio for a wide array of prescription drug compositions. For more information, please visit www.ensysce.com.
Ensysce Biosciences logo

Company profile

Ticker
ENSC, ENSCW
Exchange
NASDAQ
Website
ensysce.com
CEO
Daniel B. Silvers
Employees
Incorporated
Delaware
Location
California
Fiscal year end
Dec 31
Sector
Manufacturing > Pharmaceutical Preparation Manufacturing
Industry (SIC)
Pharmaceutical Preparations
Pfizer • Johnson & Johnson • Merck & Co • Abbott Laboratories • Teva- Pharmaceutical Industries • Bristol-Myers Squibb • Lilly(Eli) & Co • Viatris • Abbvie • Celgene ...
Former names
Leisure Acquisition Corp.
SEC CIK
0001716947
Corporate docs
Articles of Incorporation & Bylaws
Underwriting Agreements
Plans of Reorganization
Indentures
Material Contracts & Credit Agreements
Subsidiaries Lists
Subsidiaries
Covistat, Inc. • EBI OpCo, Inc. • EBI Operating, Inc. ...

ENSC stock data

Analyst ratings and price targets

Last 3 months
Lake Street
Maintains
Buy
$8.00
17 Nov 22
Latest filings (excl ownership)
View all
8-A12G/A
Registration of securities (amended)
8 Feb 23
8-K
Ensysce Biosciences, Inc. Announces $3 Million Registered Direct Offering
7 Feb 23
424B5
Prospectus supplement for primary offering
6 Feb 23
8-K
Ensysce Biosciences Announces the Distribution of Series A Preferred Stock to Holders of its Common Stock
1 Feb 23
8-A12G
Registration of securities
1 Feb 23
8-K
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
30 Jan 23
S-3
Shelf registration
30 Jan 23
8-K
Other Events
18 Jan 23
EFFECT
Notice of effectiveness
18 Jan 23
8-K
Entry into a Material Definitive Agreement
13 Jan 23
Latest ownership filings
View all
SC 13G
Lincoln Park Capital Fund, LLC
7 Feb 23
4
BOB G GOWER
1 Feb 23
SC 13G
CVI Investments, Inc.
16 Dec 22
SC 13D/A
Silvers Daniel B.
7 Jul 22
4
William H Chang
27 Jun 22
4
Steven Robert Martin
27 Jun 22
4
Lee M. Rauch
27 Jun 22
4
BOB G GOWER
27 Jun 22
4
Curtis Rosebraugh
27 Jun 22
4
Andrew Benton
27 Jun 22

Financial summary

Financial statements Chart ENSC financial data
Quarter (USD) Sep 22 Jun 22 Mar 22 Dec 21
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS
Annual (USD) Dec 21 Dec 20 Dec 19 Dec 18
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS
Cash burn rate (est.) Burn method: Change in cash Burn method: Operating income Burn method: FCF (opex + capex)
Last Q Avg 4Q Last Q Avg 4Q Last Q Avg 4Q
Cash on hand (at last report) 4.50 mm 4.50 mm 4.50 mm 4.50 mm 4.50 mm 4.50 mm
Cash burn (monthly) (no burn) 195.22 k 2.05 mm 1.67 mm 2.24 mm 1.53 mm
Cash used (since last report) n/a 849.04 k 8.94 mm 7.26 mm 9.73 mm 6.65 mm
Cash remaining n/a 3.65 mm -4.43 mm -2.76 mm -5.23 mm -2.15 mm
Runway (months of cash) n/a 18.7 -2.2 -1.7 -2.3 -1.4

Beta Read what these cash burn values mean

Financial data from company earnings reports.

Institutional ownership, Q3 2022

ENSC institutional ownership history Ownership history
73.9% owned by funds/institutions
13F holders Current Prev Q Change
Total holders 19 23 -17.4%
Opened positions 4 3 +33.3%
Closed positions 8 4 +100.0%
Increased positions 6 5 +20.0%
Reduced positions 1 2 -50.0%
13F shares Current Prev Q Change
Total value 30.39 mm 32.96 mm -7.8%
Total shares 8.47 mm 8.66 mm -2.3%
Total puts 0.00 0.00
Total calls 10.70 k 81.50 k -86.9%
Total put/call ratio – – –
Largest owners Shares Value Change
Silvers Daniel B. 2.88 mm $2.50 mm 0.0%
HG Vora Capital Management 2.46 mm $529.00 k 0.0%
Hydra LAC 1.87 mm $27.07 mm 0.0%
Vanguard 315.83 k $68.00 k +158.1%
BLK Blackrock 234.24 k $50.00 k 0.0%
SF Stifel Financial 216.64 k $47.00 k 0.0%
Cerity Partners 150.00 k $32.00 k NEW
Geode Capital Management 130.52 k $28.00 k +2.5%
UBS UBS Group AG - Registered Shares 52.14 k $11.00 k +205.2%
NTRS Northern Trust 51.09 k $11.00 k NEW
Largest transactions Shares Bought/sold Change
Renaissance Technologies 0.00 -356.33 k EXIT
Vanguard 315.83 k +193.48 k +158.1%
Anson Funds Management 0.00 -150.66 k EXIT
Cerity Partners 150.00 k +150.00 k NEW
C Citigroup 0.00 -70.94 k EXIT
Powell Investment Advisors 0.00 -70.00 k EXIT
NTRS Northern Trust 51.09 k +51.09 k NEW
Virtu Financial 41.79 k +41.79 k NEW
STT State Street 0.00 -35.55 k EXIT
UBS UBS Group AG - Registered Shares 52.14 k +35.06 k +205.2%
Data from 13F filings, for the last complete 13F reporting period. For most recent data, click the ownership history button. Values as filed, not updated for current price. Long positions only.

Recent insider trades

ENSC insider ownership history Insider history
Date Owner Security Transaction Code Indirect 10b5-1 $Price #Shares $Value #Remaining
9 Dec 22 Bob G Gower Buy Acquire P No No 1.4 357,143 500.00 k 753,095
9 Dec 22 Bob G Gower Common Stock Grant Acquire A No No 1.4 714,286 1.00 mm 716,365
23 Jun 22 Adam Levin Stock Option Common Stock Grant Acquire A No No 0.425 15,000 6.38 k 35,000
23 Jun 22 Curtis Rosebraugh Stock Option Common Stock Grant Acquire A No No 0.425 20,000 8.50 k 35,000
23 Jun 22 Andrew Benton Stock Option Common Stock Grant Acquire A No No 0.425 15,000 6.38 k 100,850
23 Jun 22 Bob G Gower Stock Option Common Stock Grant Acquire A No No 0.425 15,000 6.38 k 41,585
Data from 3, 4 and 5 filings. Values as filed, not updated for current price.

News

From Benzinga Pro
Over $12 Million Bet On TD Holdings? Check Out These 3 Penny Stocks Insiders Are Buying
2 Feb 23
The Federal Reserve on Wednesday raised its benchmark rate by 0.25%, marking the central bank's second consecutive policy downshift. When insiders purchase or sell shares, it indicates their confidence or concern around the company's prospects. Investors and traders interested in penny stocks can consider this a factor in their overall investment or trading decision.
Why Ensysce Biosciences Stock Is Exploding Higher During Wednesday's Session
25 Jan 23
Ensysce Biosciences Inc (NASDAQ: ENSC) shares are trading higher by 21.81% to $0.82 Wednesday after the company announced initiation of the final stage of its opioid overdose protection Phase 1 study. What Else?
Nasdaq Falls 50 Points; eHealth Shares Spike Higher
25 Jan 23
U.S. stocks traded lower toward the end of trading, with the Nasdaq Composite dropping around 50 points on Wednesday. The Dow traded down 0.12% to 33,694.64 while the NASDAQ fell 0.44% to 11,284.18. The S&P 500 also fell, dropping, 0.22% to 4,008.11.
Why Grom Social Enterprises Shares Are Trading Lower By 30%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session
25 Jan 23
Nasdaq Down Over 200 Points; AT&T Posts Upbeat Earnings
25 Jan 23

Press releases

From Benzinga Pro
Ensysce Biosciences, Inc. Announces Closing of $3.0 Million Registered Direct Offering Priced at-the-Market Under NASDAQ Rules
7 Feb 23
SAN DIEGO, CA / ACCESSWIRE / February 7, 2023 / Ensysce Biosciences, Inc. (NASDAQ:ENSC) (the "Company"), a clinical-stage biotech company applying transformative chemistry to improve prescription drug safety to
Ensysce Biosciences, Inc. Announces $3 Million Registered Direct Offering
3 Feb 23
SAN DIEGO, CA / ACCESSWIRE / February 3, 2023 / Ensysce Biosciences, Inc. (NASDAQ:ENSC) (the "Company"), a clinical-stage biotech company applying transformative chemistry to improve prescription drug safety to
Ensysce Biosciences Announces the Distribution of Series A Preferred Stock to Holders of Its Common Stock
1 Feb 23
SAN DIEGO, CA / ACCESSWIRE / February 1, 2023 / Ensysce Biosciences, Inc. ("Ensysce" or the "Company") (NASDAQ:ENSC)(OTC:ENSCW), a clinical-stage biotech company applying transformative chemistry to
Thinking about buying stock in Esports Entertainment, Faraday Future Intelligent Electric, Ensysce Biosciences, NVIDIA, or Mullen Automotive?
25 Jan 23
Ensysce Biosciences Announces Initiation of Final Stage of Groundbreaking Opioid Overdose Protection Phase 1 Study
25 Jan 23
Finsight
Resources
  • Knowledgebase
  • Log In
  • Register
Company
  • About
  • Contact
  • Solutions
Products
  • Deal Roadshow
  • DealVDR
  • Evercall
  • Finsight.com
CapEdge
  • Earnings Calendar
  • Earnings Transcripts
  • EDGAR Filing Screener
  • IPO Calendar
  • Compliance
  • Privacy
  • Security
  • Terms
AngelList LinkedIn